Accessibility Statement Skip Navigation
  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing
  • Login
  • GDPR
  • Create a Free Account
Return to PRWeb homepage
  • News
  • Resources
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All News Releases
      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
  • Business & Money
      • Auto & Transportation

      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Advocacy Group Opinion
      • Animal Welfare
      • Congressional & Presidential Campaigns
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • U.S. State Policy
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Hamburger menu
  • Cision PRWeb provides efficient communication tools to continuously engage with target audiences across multiple online channels
  • Create a Free Account
    • ALL CONTACT INFO
    • Contact Us


      11AM ET Sunday – 8PM ET Friday

  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • News in Focus
    • Browse All News
    • Multimedia Gallery
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR

Cosmederm Redefines Peel Science Standard with Launch of Refinity® Skin Health System
  • USA - English


News provided by

BAM Communications

Oct 30, 2014, 09:00 ET

Share this article

Share toX

Share this article

Share toX


San Diego, Calif. (PRWEB) October 30, 2014 -- High efficacy and low irritation are no longer mutually exclusive concepts in the medical-grade skin care domain: Cosmederm, the specialty biotechnology company focusing on the development of uniquely potent topical dermatological products, today announces the launch of Refinity® Skin Health System (http://www.RefinitySkinScience.com) with patented COSMEDERM®-7 anti-irritant technology.

With the emphasis consistently being on the amount or lack of ‘downtime’ necessary after a peel treatment, we’ve introduced a new term to the industry, which is 'uptime'

Post this

Formulated with the highest available glycolic acid concentrations (50% and 70%) and a low pH (pH 1.2 and pH 0.6), the Refinity Skin Health System delivers a first-of-its-kind peel experience, for all skin types, with high potency and minimal irritation or ‘downtime.’

The COSMEDERM-7 original technology is derived from the safe, naturally occurring element strontium and has been proven in scientific studies to inhibit the sensations of stinging, itching and burning of the skin, both during and after treatments. The proprietary formula virtually eliminates the need for prior treatments or “step up” processes, and allows for the use of the highest concentration (professionally administered) AHA’s for more effective anti-aging skin benefits.

“With the emphasis consistently being on the amount or lack of ‘downtime’ necessary after a peel treatment, we’ve introduced a new term to the industry, which is ‘uptime,’” said VP of Marketing for Cosmederm Bioscience, Ramin Eghbali. “The ‘uptime’ state of being is meant to summarize the patient’s maximum ability to be up and on the go, right away—the free time to accomplish anything immediately after a powerful, but very well tolerated, Refinity peel treatment. Any medical aesthetician knows they can decrease ‘downtime’ by decreasing the effectiveness of a peel; Refinity is redefining this dated assumption by providing proven, powerful efficacy with little to no irritation, and are introducing it to Southern California med spas and physician offices this fall.”

For consumers who have never been candidates for AHA therapy due to skin sensitivity or skin type (IV-VI), Refinity is clinically proven to deliver optimal strength and efficacy, with little to no risk of post-inflammatory hyperpigmentation (PIH). In addition, even at this high level of potency, the Refinity peel can be administered as early as every two weeks, given its tolerability profile, with Refinity Home Product use in between.

The glycolic acid in the Refinity peel is untouched, un-buffered and un-neutralized which gives the consumer the highest level of efficacy with maximum uptime. The Home Care products have 15% lactic acid, also untouched, un-buffered and un-neutralized with no irritation. With Refinity Skin Health System, there have been no reported cases of PIH in test markets worldwide.

“Our family of patented analgesic and anti-inflammatory compounds has led to the development of uniquely effective products that have undergone years of laboratory and clinical testing,” said Refinity’s Chief Scientific Officer and Founder, Dr. Gary Hahn, MD.

The combination of the regenerating peels and the Refinity Daily Home Care regimen with COSMEDERM-7 technology maintains the benefits by helping to soothe skin in the days following a peel treatment. The Refinity Skin Health System has been tested to showcase the following benefits:

• High potency peel and home care with little to no irritation: Maximum Uptime
• Appropriate for all skin types: color, tone, texture
• No reports of PIH
• No need to sacrifice efficacy for tolerability
• No need to sacrifice tolerability for efficacy

The Refinity Skin Health System

Pick a peel treatment; available in a kit:
50% AHA (Glycolic) + Post-Peel Moisturizer
70% AHA (Glycolic) + Post-Peel Moisturizer

Pick a daily skin care regimen:

STEP 1: Refinity Purifying Cleanser
STEP 2: Refinity Protective Toner
STEP 3: Refinity Rejuvenating Cream with 15% lactic acid (Dry Skin)
STEP 3: Refinity Rejuvenating Lotion with 15% lactic acid (Normal Skin)
STEP 3: Refinity Rejuvenating Hydrogel with 15% lactic acid (Oily Skin)

Refinity is available to any medical spa with a clinically credentialed doctor on staff, or physician office, and can be ordered via the website or by phone.

To learn more about the COSMEDERM-7 anti-irritant technology or find a medical aesthetician or skin care physician, visit http://www.RefinitySkinScience.com or call 1.800.349.4158.
About Cosmederm®

Cosmederm Bioscience is a specialty biotechnology company focusing on the development of uniquely potent topical dermatological products. Committed to being a trusted leader in the areas of anti-aging, acne and other inflammatory skin conditions, its skin care products are the result of years of laboratory research, as well as millions of dollars in clinical and developmental costs.

With proven efficacy and technology supported by clinical studies published in peer-reviewed medical journals and textbooks, Cosmederm continues to deliver verified skin solutions nationwide.

For more information, visit http://www.RefinitySkinScience.com or call 1.800.349.4158.

Jessica Windell, BAM Communications, http://www.bamcommunications.biz, +1 (661) 733-0815, [email protected]

Modal title

Contact PRWeb

  • 11AM ET Sunday – 8PM ET Friday
  • Contact Us

About PRWeb

  • About PRWeb
  • Partners
  • Partnership Programs
  • Editorial Guidelines
  • Resources

Why PRWeb

  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing

Accounts

  • Create a Free Account
  • Log in
  • Contact Us

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921

Contact Cision

Products

About

My Services
  • All News Releases
  • Online Member Center
  • ProfNet
Cision Distribution Helpline
888-776-0942
  • Legal
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 Cision US Inc.